Characterization of Epstein-Barr virus Type I variants based on linked polymorphism among EBNA3A, -3B, and -3C genes

Virus Research

Volumn 118, Issue 1-2, 2006, Pages 105-114

  Görzer, Irene ^a   Niesters, Hubert G M ^b   Cornelissen, Jan J ^b   Puchhammer Stöckl, Elisabeth ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

EBNA3; EBV; Linked polymorphism; Sequence variation

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 3A; EPSTEIN BARR VIRUS ANTIGEN 3B; EPSTEIN BARR VIRUS ANTIGEN 3C; GENE PRODUCT; LATENT MEMBRANE PROTEIN 1; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHILD; CONTROLLED STUDY; DNA POLYMORPHISM; EPSTEIN BARR VIRUS; EUROPE; GENE SEQUENCE; GENETIC LINKAGE; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; VIRUS GENE; VIRUS INFECTION; VIRUS REACTIVATION; VIRUS STRAIN;

ADOLESCENT; ADULT; AGED; AMINO ACID SEQUENCE; ANTIGENS, VIRAL; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; EVOLUTION, MOLECULAR; HERPESVIRUS 4, HUMAN; HUMANS; LINKAGE (GENETICS); MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHYLOGENY; POLYMORPHISM, GENETIC; RECOMBINATION, GENETIC; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 33646030897     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2005.11.020     Document Type: Article

References (59)

1. Aitken C., Sengupta S.K., Aedes C., Moss D.J., and Sculley T.B. Heterogeneity within the Epstein-Barr virus nuclear antigen 2 gene in different strains of Epstein-Barr virus. J. Gen. Virol. 75 (1994) 95-100
2. Babcock G.J., Decker L.L., Volk M., and Thorley-Lawson D.A. EBV persistence in memory B cells in vivo. Immunity 9 (1998) 395-404
3. Baer R., Bankier A.T., Biggin M.D., Deininger P., Farrell P., Gibson T., Hatful G., Satchwell S., Seguin C., Tuffnell P., and Barrell P. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310 (1984) 207-211
4. Brooks J.M., Croom-Carter D.S., Leese A.M., Tierney R.J., Habeshaw G., and Rickinson A.B. Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains. J. Virol. 74 (2000) 1801-1809
5. Cooper A., Johannsen E., Maruo S., Cahir-McFarland E., Illanes D., Davidson D., and Kieff E. EBNA3A association with RBP-Jkappa down-regulates c-myc and Epstein-Barr virus-transformed lymphoblast growth. J. Virol. 77 (2003) 999-1010
6. Dalbies-Tran R., Stigger-Rosser E., Dotson T., and Sample C.E. Amino acids of Epstein-Barr virus nuclear antigen 3A essential for repression of Jkappa-mediated transcription and their evolutionary conservation. J. Virol. 75 (2001) 90-99
7. Edwards R.H., Seillier-Moiseiwitsch F., and Raab-Traub N. Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains. Virology 261 (1999) 79-95
8. Fielding C.A., Sandvej K., Mehl A., Brennan P., Jones M., and Rowe M. Epstein-Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways. J. Virol. 75 (2001) 9129-9141
9. Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl. Acids. Symp. Ser. 41 (1999) 95-98
10. Hickabottom M., Parker G.A., Freemont P., Crook T., and Allday M.J. Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxyl-terminal-binding protein (CtBP). J. Biol. Chem. 277 (2002) 47197-47204
11. Hu L.F., Chen F., Zheng X., Ernberg I., Cao S.L., Christensson B., Klein G., and Winberg G. Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene 8 (1993) 1575-1583
12. Kaye K.M., Izumi K.M., and Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 9150-9154
13. Khan G., Miyashita E.M., Yang B., Babcock G.J., and Thorley-Lawson D.A. Is EBV persistence in vivo a model for B cell homeostasis?. Immunity 2 (1996) 173-179
14. Khanim F., Yao Q.Y., Niedobitek G., Sihota S., Rickinson A.B., and Young L.S. Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood 88 (1996) 3491-3501
15. Khanna R., Moss D.J., and Burrows S.R. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol. Rev. 170 (1999) 49-64
16. Khanna R., Slade R.W., Poulsen L., Moss D.J., Burrows S.R., Nicholls J., and Burrows J.M. Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: evidence for immune pressure-independent genetic drift. J. Virol. 71 (1997) 8340-8346
17. Kieff E., and Rickinson A.B. Epstein-Barr virus and its replication. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. Fourth ed. (2001), Lippincott Williams and Wilkins, Philadelphia 2511-2574
18. Knecht H., Berger C., Rothenberger S., Odermatt B.F., and Brousset P. The role of Epstein-Barr virus in neoplastic transformation. Oncology 60 (2001) 289-302
19. Knight J.S., Lan K., Subramanian C., and Robertson E.S. Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J. Virol. 77 (2003) 4261-4272
20. Krauer K.G., Kienzle N., Young D.B., and Sculley T.B. Epstein-Barr nuclear antigen-3 and -4 interact with RBP-2N, a major isoform of RBP-Jkappa in B lymphocytes. Virology 226 (1996) 346-353
21. Küppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat. Rev. Immunol. 3 (2003) 801-812
22. Kulwichit W., Edwards R.H., Davenport E.M., Baskar J.F., Godfrey V., and Raab-Traub N. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 11963-11968
23. Kumar S., Tamura K., Jakobsen I.B., and Nei M. MEGA2: Molecular Evolutionary Genetics Analysis Software (2001), Arizona State University, Tempe, Arizona, USA
24. Lennette E.H., and Schmidt N.J. Diagnostic procedures for viral, rickettsial, and chlamydial infections. Fifth ed. (1979), American Public Health Association, Washington, DC
25. Le Roux A., Kerdiles B., Wall D., Dedieu J.F., and Perricaudet M. The Epstein-Barr virus determined nuclear antigens EBNA-3A, -3B, and -3C repress EBNA-2-mediated transactivation of the viral terminal protein 1 gene promoter. Virology 205 (1994) 596-602
26. Lin J., Johannsen E., Robertson E., and Kieff E. Epstein-Barr virus nuclear antigen 3C putative repression domain mediates coactivation of the LMP1 promoter with EBNA-2. J. Virol. 76 (2002) 2332-2342
27. Macsween K.F., and Crawford D.H. Epstein-Barr virus-recent advances. Lancet Infect. Dis. 3 (2003) 131-140
28. Manet E., Bourillot P.Y., Waltzer L., and Sergeant A. EBV genes and B cell proliferation. Crit. Rev. Oncol. Hematol. 28 (1998) 129-137
29. Maruo S., Johannsen E., Illanes D., Cooper A., Zhao B., and Kieff E. Epstein-Barr virus nuclear protein 3A domains essential for growth of lymphoblasts: transcriptional regulation through RBP-Jkappa/CBF1 is critical. J. Virol. 79 (2005) 10171-10179
30. Midgley R.S., Blake N.W., Yao Q.Y., Croom-Carter D., Cheung S.T., Leung S.F., Chan A.T., Johnson P.J., Huang D., Rickinson A.B., and Lee S.P. Novel intertypic recombinants of epstein-barr virus in the Chinese population. J. Virol. 74 (2000) 1544-1548
31. Midgley R.S., Bell A.I., McGeoch D.J., and Rickinson A.B. Latent gene sequencing reveals familial relationships among Chinese Epstein-Barr virus strains and evidence for positive selection of A11 epitope changes. J. Virol. 77 (2003) 11517-11530
32. Miller W.E., Edwards R.H., Walling D.M., and Raab-Traub N. Sequence variation in the Epstein-Barr virus latent membrane protein 1. J. Gen. Virol. 75 (1994) 2729-2740
33. Moss D.J., Burrows S.R., Silins S.L., Misko I., and Khanna R. The immunology of Epstein-Barr virus infection. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356 (2001) 475-488
34. Radkov S.A., Bain M., Farrell P.J., West M., Rowe M., and Allday M.J. Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J. Virol. 71 (1997) 8552-8562
35. Radkov S.A., Touitou R., Brehm A., Rowe M., West M., Kouzarides T., and Allday M.J. Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J. Virol. 73 (1999) 5688-5697
36. Robertson E.S., Lin J., and Kieff E. The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). J. Virol. 70 (1996) 3068-3074
37. Sample J., Young L., Martin B., Chatman T., Kieff E., Rickinson A., and Kieff E. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J. Virol. 64 (1990) 4084-4092
38. Sandvej K., Gratama J.W., Munch M., Zhou X.G., Bolhuis R.L., Andresen B.S., Gregersen N., and Hamilton-Dutoit S. Sequence analysis of the Epstein-Barr virus (EBV) latent membrane protein-1 gene and promoter region: identification of four variants among wild-type EBV isolates. Blood 90 (1997) 323-330
39. Schuster V., Seidenspinner S., and Kreth H.W. Detection of a nuclear antigen 2 (EBNA2)-variant Epstein-Barr virus strain in two siblings with fatal lymphoproliferative disease. J. Med. Virol. 48 (1996) 114-120
40. Sculley T.B., Apolloni A., Hurren L., Moss D.J., and Cooper D.A. Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects. J. Infect. Dis. 162 (1990) 643-648
41. Sitki-Green D., Covington M., and Raab-Traub N. Compartmentalization and transmission of multiple epstein-barr virus strains in asymptomatic carriers. J. Virol. 77 (2003) 1840-1847
42. Tao Q., Yang J., Huang H., Swinnen L.J., and Ambinder R.F. Conservation of Epstein-Barr virus cytotoxic T-cell epitopes in posttransplant lymphomas: implications for immune therapy. Am. J. Pathol. 160 (2002) 1839-1845
43. Thompson J.D., Gibson T.J., Plewniak F., Jeanmougin F., and Higgins D.G. The ClustalX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25 (1997) 4876-4882
44. Tomkinson B., Robertson E., and Kieff E. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J. Virol. 67 (1993) 2014-2025
45. Touitou R., Hickabottom M., Parker G., Crook T., and Allday M.J. Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C. J. Virol. 75 (2001) 7749-7755
46. Trivedi P., Hu L.F., Chen F., Christensson B., Masucci M.G., Klein G., and Winberg G. Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. Eur. J. Cancer 30A (1994) 84-88
47. Van Esser J.W., Niesters H.G., Thijsen S.F., Meijer E., Osterhaus A.D., Wolthers K.C., Boucher C.A., Gratama J.W., Budel L.M., Van der Holt B., Van Loon A.M., Lowenberg B., Verdonck L.F., and Cornelissen J.J. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br. J. Haematol. 113 (2001) 814-821
48. Walling D.M., Edmiston S.N., Sixbey J.W., Abdel-Hamid M., Resnick L., and Raab-Traub N. Coinfection with multiple strains of the Epstein-Barr virus in human immunodeficiency virus-associated hairy leukoplakia. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 6560-6564
49. Walling D.M., Perkins A.G., Webster-Cyriaque J., Resnick L., and Raab-Traub N. The Epstein-Barr virus EBNA-2 gene in oral hairy leukoplakia: strain variation, genetic recombination, and transcriptional expression. J. Virol. 68 (1994) 7918-7926
50. Walling D.M., Shebib N., Weaver S.C., Nichols C.M., Flaitz C.M., and Webster-Cyriaque J. The molecular epidemiology and evolution of Epstein-Barr virus: sequence variation and genetic recombination in the latent membrane protein-1 gene. J. Infect. Dis. 179 (1999) 763-774
51. Walling D.M., Brown A.L., Etienne W., Keitel W.A., and Ling P.D. Multiple Epstein-Barr virus infections in healthy individuals. J. Virol. 77 (2003) 6546-6550
52. Waltzer L., Perricaudet M., Sergeant A., and Manet E. Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-Jkappa-EBNA2-activated transcription by inhibiting the binding of RBP-Jkappa to DNA. J. Virol. 70 (1996) 5909-5915
53. Wang D., Liebowitz D., and Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43 (1985) 831-840
54. West M.J., Webb H.M., Sinclair A.J., and Woolfson D.N. Biophysical and mutational analysis of the putative bZIP domain of Epstein-Barr virus EBNA 3C. J. Virol. 78 (2004) 9431-9445
55. Yao Q.Y., Tierney R.J., Croom-Carter D., Dukers D., Cooper G.M., Ellis C.J., Rowe M., and Rickinson A.B. Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals. J. Virol. 70 (1996) 4884-4894
56. Young L.S., and Murray P.G. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22 (2003) 5108-5121
57. Young L.S., and Rickinson A.B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4 (2004) 757-768
58. Zhao B., Marshall D.R., and Sample C.E. A conserved domain of the Epstein-Barr virus nuclear antigens 3A and 3C binds to a discrete domain of Jkappa. J. Virol. 70 (1996) 4228-4236
59. Zhao B., and Sample C.E. Epstein-Barr virus nuclear antigen 3C activates the latent membrane protein 1 promoter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an spi-1/Spi-B binding site. J. Virol. 74 (2000) 5151-5160